Improved Treatment for Patients With Long-term Opioid Therapy for Non-cancer Pain in Primary Care
NCT ID: NCT06856733
Last Updated: 2025-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
110 participants
INTERVENTIONAL
2025-03-10
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?
Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.
Participants will receive a person-centred team-based treatment consisting of:
* Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
* Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
* Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Opioid Therapy in Chronic Non-Cancer Pain: Risks and Benefits
NCT06063902
Health Outcomes From Opioid Therapy for Chronic Pain
NCT00495404
A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Opioids for the Treatment of Chronic Pain
NCT02751762
Access to Primary Care for People With Opioid Use Disorder
NCT05484609
Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up
NCT03485430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective:
To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care
Trial design and setting:
This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).
This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.
Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.
No interventions assigned to this group
Intervention
Phase 1 (investigation and assessment, week 1-3):
* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
* A visit to a care manager
Phase 2 (treatment plan, week 3-4):
\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.
Phase 3 (treatment and follow-up, week 4-24):
* Implementation of the individualized rehabilitation plan.
* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
* A second team consultation half-way
Person-centred team-based approach
Phase 1 (investigation and assessment, week 1-3):
* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
* A visit to a care manager
Phase 2 (treatment plan, week 3-4):
\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.
Phase 3 (treatment and follow-up, week 4-24):
* Implementation of the individualized rehabilitation plan.
* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
* A second team consultation half-way
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Person-centred team-based approach
Phase 1 (investigation and assessment, week 1-3):
* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
* A visit to a care manager
Phase 2 (treatment plan, week 3-4):
\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.
Phase 3 (treatment and follow-up, week 4-24):
* Implementation of the individualized rehabilitation plan.
* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
* A second team consultation half-way
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to speak Swedish or English
Exclusion Criteria
* No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
* Using their opioids for cancer pain
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uppsala University
OTHER
Uppsala County Council, Sweden
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Kempen
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Region Uppsala
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Opi-Prim
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.